Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06404840
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-05-05
Brief Title:
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases A Prospective Single-Arm Phase II Study
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases PCLM A Prospective Single-Arm Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with PCLM account for the majority of our departments pancreatic cancer cases and often have limited surgical options due to the aggressive nature of their tumors For those with good performance status ECOG PS 0-1 NCCN recommends gemcitabine nab-paclitaxel AG Though nimotuzumab combined with gemcitabine improves survival there remains scarce clinical data regarding its efficacy in conjunction with AG for treating PCLM This study aims to evaluate the safety and efficacy of incorporating nimotuzumab with AG for PCLM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None